Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

FDA Issues Draft Guidance on Risk Evaluation and Mitigation Strategies

By Pharmaceutical Processing | October 1, 2009

The FDA has announced the availability of the first draftguidance for industry on Risk Evaluation and Mitigation Strategies or REMS,which are required for certain drugs or biologics. The Food and Drug Administration Amendments Act of 2007 (FDAAA) grantedthe FDA the authority to require the submission and implementation of a REMSif the FDA determines a REMS is necessary to ensure that a drug’s benefitsoutweigh its risks. REMS components include medication guides; patient package inserts; acommunication plan for health care providers; elements to ensure safe useincluding requirements for those who prescribe, dispense, or use the drug; anda timetable for REMS submission. The draft guidance for industry titled “Format and Content of ProposedRisk Evaluation and Mitigation Strategies (REMS), REMS Assessments, andProposed REMS Modifications”: — provides FDA’s current thinking on the format and content thatindustry should use for submissions of proposed REMS — describes each potential element — includes preliminary information on the content of assessments andproposed modifications of approved REMS — describes REMS policies for certain regulatory situations — informs industry about who to contact within FDA about a REMS — indicates FDA Web sites where documents about approved REMS will beposted — provides an example of what an approved REMS might look like for afictitious product. “With this new guidance, manufacturers will have a useful blueprint forhow to develop these important safety strategies,” said Janet Woodcock, M.D.,director of the FDA’s Center for Drug Evaluation and Research. The draft guidance is available athttp://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM184128.pdf

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards